<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00929708</url>
  </required_header>
  <id_info>
    <org_study_id>D0570C00003</org_study_id>
    <nct_id>NCT00929708</nct_id>
  </id_info>
  <brief_title>Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <acronym>GLAD</acronym>
  <official_title>A 4-week, Phase-II, Double-blind, Placebo-controlled, Randomised, Parallel-group, Multi-centre Study to Assess the Efficacy and Tolerability/Safety of Inhaled AZD3199 Once Daily Compared to 9 μg Formoterol Bid and Placebo in Patients With Moderate to Severe COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy, safety and tolerability of 4 weeks
      treatment with AZD3199 in moderate to severe COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1, E0−4; the Average Value at Visit 5 From Before to 4 Hours After Morning Dose (Peak Effect)</measure>
    <time_frame>0,5 min, 15 min, 60 min, 2 h, 4 h</time_frame>
    <description>change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1, E24−26; the Average Value at Visit 5 Between 24 and 26 Hours Following the Morning Dose (Trough Effect)</measure>
    <time_frame>24h, 26h</time_frame>
    <description>change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax; the Highest Plasma Concentration of AZD3199 Measured</measure>
    <time_frame>0,15 min, 1, 4 and 24 hours post dose</time_frame>
    <description>PK is only measured for AZD3199</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24; Area Under the Plasma Concentration Curve From Zero to 24 Hours After Dose</measure>
    <time_frame>0,15 min, 1, 4 and 24 hours post dose</time_frame>
    <description>PK is only measured for AZD3199</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Post Salbutamol Inhalation</measure>
    <time_frame>Baseline (visit 2) and 26 h after the last morning dose (visit 5).</time_frame>
    <description>Mean value of FEV1 pre and post salbutamol at visit 2 and visit 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Reliever Medication Inhalations Per 24h</measure>
    <time_frame>During day (from rising from bed until going to bed) and night (from going to bed until rising from bed) at visit 1 to visit 5 (24h), up to 4 weeks.</time_frame>
    <description>Change from run-in</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total AstraZeneca COPD Symptoms Scores (Included Breathlessness, Chest Tightness, Cough and Night-time Awakenings)</measure>
    <time_frame>Daily, during run-in and treatment</time_frame>
    <description>Score on a scale 5-point Likert-type scale, ranging from 0 (none) to 4 (severe) for each symptom, total score is the sum of each symptom ranged from 0 to 16. Change from run-in.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mean CCQ (Clinical COPD Questionnaire)</measure>
    <time_frame>Mean over week 0, mean over week 1, mean over week 2, and mean over week 4</time_frame>
    <description>Change from baseline to treatment in score. The total scores vary between 0 (never/not limited at all) to 6 (almost all the time/totally limited). The data below represent the average of week 1,2,4 minus week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Score SGRQ-C (St George's Respiratory Questionnaire for COPD)</measure>
    <time_frame>At baseline (visit 2) and after 4 weeks of treatment (visit 5).</time_frame>
    <description>The total score is calculated using all questions including their weights and scores range from 0 (perfect health) to 100 (worst possible state)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">329</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD3199 low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD3199 intermediate dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD3199 high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol 2x4.5 microgram bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3199</intervention_name>
    <description>Dry powder for inhalation, o.d., 4 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>formoterol</intervention_name>
    <description>Dry powder for inhalation, b.i.d., 4 weeks</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dry powder for inhalation, b.i.d., 4 weeks</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD

          -  Current or exsmokers, 10 pack years

        Exclusion Criteria:

          -  Asthma

          -  Any clinically relevant abnormal findings at screening examinations

          -  Recent COPD exacerbation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Kuna, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lodz, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blagoevgrad</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Russe</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pointe-claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-romuald</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trois Rivieres</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yanagawa</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuyama</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chitose</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Obihiro</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomakomai</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hitachi</city>
        <state>Ibaragi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Naka-gun</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyonaka</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moriyama</city>
        <state>Shiga</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Otsu</city>
        <state>Shiga</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Machida</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kitakyusyu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>BIAlYSTOK</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gorzow Wlkp</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>POZNAn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarnow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2009</study_first_submitted>
  <study_first_submitted_qc>June 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2009</study_first_posted>
  <results_first_submitted>December 20, 2012</results_first_submitted>
  <results_first_submitted_qc>December 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 17, 2014</results_first_posted>
  <last_update_submitted>January 22, 2014</last_update_submitted>
  <last_update_submitted_qc>January 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Inhalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>AZD-3199</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study has been performed at 53 centres in Bulgaria, Canada, Japan, Poland and Russian Federation. The recruitment period was between 16 June 2009 and 8 January 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD3199 200 Mcg od</title>
          <description>2 x AZD3199 Turbuhaler 100 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
        </group>
        <group group_id="P2">
          <title>AZD3199 400 Mcg od</title>
          <description>2 x AZD3199 Turbuhaler 200 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
        </group>
        <group group_id="P3">
          <title>AZD3199 800 Mcg od</title>
          <description>2 x AZD3199 Turbuhaler 400 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
        </group>
        <group group_id="P4">
          <title>Formoterol 9 Mcg Bid</title>
          <description>2 x Oxis Turbuhaler 4.5 mcg (morning) + 2 x Oxis Turbuhaler 4.5 mcg (evening)</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>2 x placebo Turbuhaler (morning) + 2 x placebo Turbuhaler (evening)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="67"/>
                <participants group_id="P5" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="61"/>
                <participants group_id="P5" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD3199 200 Mcg od</title>
          <description>2 x AZD3199 Turbuhaler 100 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
        </group>
        <group group_id="B2">
          <title>AZD3199 400 Mcg od</title>
          <description>2 x AZD3199 Turbuhaler 200 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
        </group>
        <group group_id="B3">
          <title>AZD3199 800 Mcg od</title>
          <description>2 x AZD3199 Turbuhaler 400 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
        </group>
        <group group_id="B4">
          <title>Formoterol 9 Mcg Bid</title>
          <description>2 x Oxis Turbuhaler 4.5 mcg (morning) + 2 x Oxis Turbuhaler 4.5 mcg (evening)</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>2 x placebo Turbuhaler (morning) + 2 x placebo Turbuhaler (evening)</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="65"/>
            <count group_id="B4" value="67"/>
            <count group_id="B5" value="63"/>
            <count group_id="B6" value="329"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" lower_limit="45" upper_limit="81"/>
                    <measurement group_id="B2" value="63.8" lower_limit="40" upper_limit="82"/>
                    <measurement group_id="B3" value="65.3" lower_limit="41" upper_limit="92"/>
                    <measurement group_id="B4" value="64.1" lower_limit="47" upper_limit="77"/>
                    <measurement group_id="B5" value="64.8" lower_limit="46" upper_limit="84"/>
                    <measurement group_id="B6" value="63.85" lower_limit="62.4" upper_limit="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1, E0−4; the Average Value at Visit 5 From Before to 4 Hours After Morning Dose (Peak Effect)</title>
        <description>change from baseline</description>
        <time_frame>0,5 min, 15 min, 60 min, 2 h, 4 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 200 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 100 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 400 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 200 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 800 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 400 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 Mcg Bid</title>
            <description>2 x Oxis Turbuhaler 4.5 mcg (morning) + 2 x Oxis Turbuhaler 4.5 mcg (evening)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 x placebo Turbuhaler (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1, E0−4; the Average Value at Visit 5 From Before to 4 Hours After Morning Dose (Peak Effect)</title>
          <description>change from baseline</description>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.33"/>
                    <measurement group_id="O2" value="0.17" spread="0.31"/>
                    <measurement group_id="O3" value="0.14" spread="0.27"/>
                    <measurement group_id="O4" value="0.16" spread="0.22"/>
                    <measurement group_id="O5" value="0.03" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>FEV1, E24−26; the Average Value at Visit 5 Between 24 and 26 Hours Following the Morning Dose (Trough Effect)</title>
        <description>change from baseline</description>
        <time_frame>24h, 26h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 200 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 100 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 400 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 200 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 800 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 400 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 Mcg Bid</title>
            <description>2 x Oxis Turbuhaler 4.5 mcg (morning) + 2 x Oxis Turbuhaler 4.5 mcg (evening)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 x placebo Turbuhaler (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1, E24−26; the Average Value at Visit 5 Between 24 and 26 Hours Following the Morning Dose (Trough Effect)</title>
          <description>change from baseline</description>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.31"/>
                    <measurement group_id="O2" value="0.12" spread="0.28"/>
                    <measurement group_id="O3" value="0.11" spread="0.25"/>
                    <measurement group_id="O4" value="0.03" spread="0.23"/>
                    <measurement group_id="O5" value="0.01" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax; the Highest Plasma Concentration of AZD3199 Measured</title>
        <description>PK is only measured for AZD3199</description>
        <time_frame>0,15 min, 1, 4 and 24 hours post dose</time_frame>
        <population>AZD3199 plasma data were available for 178 of the 199 randomized patients, but data from 2 patients in AZD3199 200 mcg group were excluded from analysis because most of the values were below LOQ.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 200 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 100 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 400 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 200 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 800 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 400 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 Mcg Bid</title>
            <description>2 x Oxis Turbuhaler 4.5 mcg (morning) + 2 x Oxis Turbuhaler 4.5 mcg (evening)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 x placebo Turbuhaler (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax; the Highest Plasma Concentration of AZD3199 Measured</title>
          <description>PK is only measured for AZD3199</description>
          <population>AZD3199 plasma data were available for 178 of the 199 randomized patients, but data from 2 patients in AZD3199 200 mcg group were excluded from analysis because most of the values were below LOQ.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" lower_limit="0.03" upper_limit="3.6"/>
                    <measurement group_id="O2" value="1.88" lower_limit="0.05" upper_limit="9.8"/>
                    <measurement group_id="O3" value="4.01" lower_limit="0.12" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-24; Area Under the Plasma Concentration Curve From Zero to 24 Hours After Dose</title>
        <description>PK is only measured for AZD3199</description>
        <time_frame>0,15 min, 1, 4 and 24 hours post dose</time_frame>
        <population>AZD3199 plasma data were available for 178 of the 199 randomized patients, but data from 2 patients in AZD3199 200 mcg group were excluded from analysis because most of the values were below LOQ.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 200 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 100 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 400 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 200 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 800 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 400 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 Mcg Bid</title>
            <description>2 x Oxis Turbuhaler 4.5 mcg (morning) + 2 x Oxis Turbuhaler 4.5 mcg (evening)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 x placebo Turbuhaler (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24; Area Under the Plasma Concentration Curve From Zero to 24 Hours After Dose</title>
          <description>PK is only measured for AZD3199</description>
          <population>AZD3199 plasma data were available for 178 of the 199 randomized patients, but data from 2 patients in AZD3199 200 mcg group were excluded from analysis because most of the values were below LOQ.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" lower_limit="0.4" upper_limit="20.8"/>
                    <measurement group_id="O2" value="8.69" lower_limit="0.7" upper_limit="54.1"/>
                    <measurement group_id="O3" value="14.82" lower_limit="1.4" upper_limit="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Post Salbutamol Inhalation</title>
        <description>Mean value of FEV1 pre and post salbutamol at visit 2 and visit 5</description>
        <time_frame>Baseline (visit 2) and 26 h after the last morning dose (visit 5).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 200 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 100 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 400 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 200 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 800 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 400 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 Mcg Bid</title>
            <description>2 x Oxis Turbuhaler 4.5 mcg (morning) + 2 x Oxis Turbuhaler 4.5 mcg (evening)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 x placebo Turbuhaler (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Post Salbutamol Inhalation</title>
          <description>Mean value of FEV1 pre and post salbutamol at visit 2 and visit 5</description>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.060" spread="0.306"/>
                    <measurement group_id="O2" value="0.073" spread="0.358"/>
                    <measurement group_id="O3" value="0.077" spread="0.238"/>
                    <measurement group_id="O4" value="0.048" spread="0.260"/>
                    <measurement group_id="O5" value="0.018" spread="0.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Reliever Medication Inhalations Per 24h</title>
        <description>Change from run-in</description>
        <time_frame>During day (from rising from bed until going to bed) and night (from going to bed until rising from bed) at visit 1 to visit 5 (24h), up to 4 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 200 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 100 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 400 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 200 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 800 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 400 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 Mcg Bid</title>
            <description>2 x Oxis Turbuhaler 4.5 mcg (morning) + 2 x Oxis Turbuhaler 4.5 mcg (evening)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 x placebo Turbuhaler (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Reliever Medication Inhalations Per 24h</title>
          <description>Change from run-in</description>
          <units>Number of reliver inh.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="1.85"/>
                    <measurement group_id="O2" value="-1.23" spread="1.96"/>
                    <measurement group_id="O3" value="-1.15" spread="1.55"/>
                    <measurement group_id="O4" value="-0.66" spread="1.40"/>
                    <measurement group_id="O5" value="-0.23" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total AstraZeneca COPD Symptoms Scores (Included Breathlessness, Chest Tightness, Cough and Night-time Awakenings)</title>
        <description>Score on a scale 5-point Likert-type scale, ranging from 0 (none) to 4 (severe) for each symptom, total score is the sum of each symptom ranged from 0 to 16. Change from run-in.</description>
        <time_frame>Daily, during run-in and treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 200 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 100 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 400 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 200 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 800 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 400 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 Mcg Bid</title>
            <description>2 x Oxis Turbuhaler 4.5 mcg (morning) + 2 x Oxis Turbuhaler 4.5 mcg (evening)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 x placebo Turbuhaler (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
        </group_list>
        <measure>
          <title>Total AstraZeneca COPD Symptoms Scores (Included Breathlessness, Chest Tightness, Cough and Night-time Awakenings)</title>
          <description>Score on a scale 5-point Likert-type scale, ranging from 0 (none) to 4 (severe) for each symptom, total score is the sum of each symptom ranged from 0 to 16. Change from run-in.</description>
          <units>total score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="1.34"/>
                    <measurement group_id="O2" value="-0.91" spread="1.65"/>
                    <measurement group_id="O3" value="-1.21" spread="1.53"/>
                    <measurement group_id="O4" value="-0.56" spread="1.83"/>
                    <measurement group_id="O5" value="-0.43" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Mean CCQ (Clinical COPD Questionnaire)</title>
        <description>Change from baseline to treatment in score. The total scores vary between 0 (never/not limited at all) to 6 (almost all the time/totally limited). The data below represent the average of week 1,2,4 minus week 0.</description>
        <time_frame>Mean over week 0, mean over week 1, mean over week 2, and mean over week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 200 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 100 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 400 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 200 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 800 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 400 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 Mcg Bid</title>
            <description>2 x Oxis Turbuhaler 4.5 mcg (morning) + 2 x Oxis Turbuhaler 4.5 mcg (evening)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 x placebo Turbuhaler (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mean CCQ (Clinical COPD Questionnaire)</title>
          <description>Change from baseline to treatment in score. The total scores vary between 0 (never/not limited at all) to 6 (almost all the time/totally limited). The data below represent the average of week 1,2,4 minus week 0.</description>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.49"/>
                    <measurement group_id="O2" value="-0.29" spread="0.65"/>
                    <measurement group_id="O3" value="-0.39" spread="0.54"/>
                    <measurement group_id="O4" value="-0.35" spread="0.65"/>
                    <measurement group_id="O5" value="-0.10" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Score SGRQ-C (St George’s Respiratory Questionnaire for COPD)</title>
        <description>The total score is calculated using all questions including their weights and scores range from 0 (perfect health) to 100 (worst possible state)</description>
        <time_frame>At baseline (visit 2) and after 4 weeks of treatment (visit 5).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 200 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 100 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 400 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 200 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 800 Mcg od</title>
            <description>2 x AZD3199 Turbuhaler 400 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 Mcg Bid</title>
            <description>2 x Oxis Turbuhaler 4.5 mcg (morning) + 2 x Oxis Turbuhaler 4.5 mcg (evening)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>2 x placebo Turbuhaler (morning) + 2 x placebo Turbuhaler (evening)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Score SGRQ-C (St George’s Respiratory Questionnaire for COPD)</title>
          <description>The total score is calculated using all questions including their weights and scores range from 0 (perfect health) to 100 (worst possible state)</description>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="58"/>
                <count group_id="O5" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.10" spread="13.67"/>
                    <measurement group_id="O2" value="-8.17" spread="12.18"/>
                    <measurement group_id="O3" value="-5.01" spread="10.69"/>
                    <measurement group_id="O4" value="-5.16" spread="10.88"/>
                    <measurement group_id="O5" value="-2.35" spread="12.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD3199 200 Mcg od</title>
          <description>2 x AZD3199 Turbuhaler 100 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
        </group>
        <group group_id="E2">
          <title>AZD3199 400 Mcg od</title>
          <description>2 x AZD3199 Turbuhaler 200 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
        </group>
        <group group_id="E3">
          <title>AZD3199 800 Mcg od</title>
          <description>2 x AZD3199 Turbuhaler 400 mcg (morning) + 2 x placebo Turbuhaler (evening)</description>
        </group>
        <group group_id="E4">
          <title>Formoterol 9 Mcg Bid</title>
          <description>2 x Oxis Turbuhaler 4.5 mcg (morning) + 2 x Oxis Turbuhaler 4.5 mcg (evening)</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>2 x placebo Turbuhaler (morning) + 2 x placebo Turbuhaler (evening)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ishaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chroniv obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>An Investigator agrees to provide a copy of the publication to AZ for review at least 60 days in advance of submission for publication. Investigators in multicenter (MC) studies agree to postpone MC publications until the earlier of the date of the first AZ-authorized MC publication or a period up to 18 months from study completion at all sites. AZ has the right to request delays: up to 60 days for confidential information, and an additional 90 days to protect intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carin Jorup, MSD</name_or_title>
      <organization>AstraZeneca</organization>
      <email>clinicaltrialtransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

